Tyra Biosciences, Inc. (TYRA)Healthcare | Biotechnology | Carlsbad, United States | NasdaqGS
18.70 USD
+0.14
(0.754%)
⇧
(Oct. 14, 2026, 4 p.m.
EDT)
After hours: 18.70 |
Hot Take ↕ | Oct. 10, 2026, 11:28 a.m. EDT
The investment case for Tyra Biosciences is currently paralyzed by a severe disconnect between analyst optimism and the company's actual financial reality. While Wall Street analysts project a massive 96% upside to a $50 price target, the underlying business is bleeding cash, reporting negative free cash flow, and posting negative returns on both assets and equity. This fundamental deterioration is reflected in the stock's multi-year trajectory, which remains down 12% despite a volatile history, and is now capped by a recent year-over-year decline. Technically, the stock is trapped between a heavy cloud of put options at the $20 strike and a 50-day moving average that sits significantly higher, suggesting institutional holders are waiting for a breakdown rather than a rally. The lack of any dividend yield removes any floor for patient capital, leaving the share price entirely dependent on the success of upcoming clinical trials like SURF302. Until the company demonstrates a path to profitability or a definitive catalyst that resolves the trust deficit between management and the market, the risk-reward profile remains skewed heavily toward the downside. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.170029 |
| AutoARIMA | 0.170029 |
| MSTL | 0.178011 |
| AutoTheta | 0.182426 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 3.94 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.248 |
| Excess Kurtosis | 0.01 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.578 |
| Market Cap | 1,285,736,064 |
| Forward P/E | -6.75 |
| Beta | 0.75 |
| Website | https://tyra.bio |
As of Oct. 10, 2026, 11:28 a.m. EDT: Speculators are positioning defensively with heavy put volume at the $20 strike, creating a significant wall of resistance just above current prices. While there is some call interest at higher strikes ($27.50, $35.00), the overwhelming open interest concentration in puts suggests a fear of further downside rather than a bullish breakout. Implied volatility is elevated relative to deep out-of-the-money calls, indicating the market is pricing in a high probability of a drop or stagnation.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.2506739 |
| Address1 | 2,656 State Street |
| All Time High | 40.65 |
| All Time Low | 4.93 |
| Ask | 23.47 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 707,320 |
| Average Daily Volume3 Month | 855,130 |
| Average Volume | 855,130 |
| Average Volume10Days | 707,320 |
| Beta | 0.751 |
| Bid | 13.45 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 5.928 |
| City | Carlsbad |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 18.7 |
| Current Ratio | 14.905 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 18.78 |
| Day Low | 18.25 |
| Debt To Equity | 1.578 |
| Display Name | Tyra Biosciences |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda | -159,922,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -4.8 |
| Enterprise Value | 767,596,736 |
| Eps Current Year | -2.6365 |
| Eps Forward | -2.77064 |
| Eps Trailing Twelve Months | -2.39 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 24.2582 |
| Fifty Day Average Change | -5.558199 |
| Fifty Day Average Change Percent | -0.2291266 |
| Fifty Two Week Change Percent | 25.067389 |
| Fifty Two Week High | 40.65 |
| Fifty Two Week High Change | -21.95 |
| Fifty Two Week High Change Percent | -0.5399754 |
| Fifty Two Week Low | 13.35 |
| Fifty Two Week Low Change | 5.3500004 |
| Fifty Two Week Low Change Percent | 0.4007491 |
| Fifty Two Week Range | 13.35 - 40.65 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,631,712,600,000 |
| Float Shares | 34,651,415 |
| Forward Eps | -2.77064 |
| Forward P E | -6.749344 |
| Free Cashflow | -63,067,124 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 87 |
| Fullday Change | 0.1400013 |
| Fullday Change Percent | 0.75431734 |
| Fullday Price | 18.7 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02428 |
| Held Percent Institutions | 1.08278 |
| Implied Shares Outstanding | 68,755,939 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-09-15 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California. |
| Long Name | Tyra Biosciences, Inc. |
| Market | us_market |
| Market Cap | 1,285,736,064 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_650787124 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -148,564,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,597,200,462 |
| Number Of Analyst Opinions | 11 |
| Open | 18.44 |
| Operating Cashflow | -109,651,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 619 728 4760 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 18.7 |
| Post Market Time | 1,792,008,066 |
| Previous Close | 18.56 |
| Price Eps Current Year | -7.092737 |
| Price Hint | 2 |
| Price To Book | 3.154521 |
| Profit Margins | 0.0 |
| Quick Ratio | 14.478 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.26667 |
| Region | US |
| Regular Market Change | 0.140001 |
| Regular Market Change Percent | 0.754317 |
| Regular Market Day High | 18.78 |
| Regular Market Day Low | 18.25 |
| Regular Market Day Range | 18.25 - 18.78 |
| Regular Market Open | 18.44 |
| Regular Market Previous Close | 18.56 |
| Regular Market Price | 18.7 |
| Regular Market Time | 1,792,008,000 |
| Regular Market Volume | 483,996 |
| Return On Assets | -0.28456 |
| Return On Equity | -0.45306998 |
| Sand P52 Week Change | 0.1570785 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 68,755,939 |
| Shares Percent Shares Out | 0.1369 |
| Shares Short | 9,414,018 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 9,440,216 |
| Short Name | Tyra Biosciences, Inc. |
| Short Percent Of Float | 0.22709998 |
| Short Ratio | 6.85 |
| Source Interval | 15 |
| State | CA |
| Symbol | TYRA |
| Target High Price | 59.0 |
| Target Low Price | 29.0 |
| Target Mean Price | 47.45455 |
| Target Median Price | 50.0 |
| Total Cash | 353,944,000 |
| Total Cash Per Share | 5.931 |
| Total Debt | 5,582,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.39 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 30.348625 |
| Two Hundred Day Average Change | -11.648624 |
| Two Hundred Day Average Change Percent | -0.3838271 |
| Type Disp | Equity |
| Volume | 483,996 |
| Website | https://tyra.bio |
| Zip | 92,008 |